

Patient name	DOB	Hospital no.	Date
--------------	-----	--------------	------

Treatment context

This maintenance treatment continues HER2 blockade to help control metastatic or unresectable recurrent HER2-positive breast cancer after chemotherapy.

Schedule

Pertuzumab and trastuzumab are given by infusion every 21 days after the chemotherapy phase of the metastatic treatment plan. Duration depends on benefit, tolerance and the agreed plan; this is not a fixed one-year adjuvant course.

1. TREATMENT DISCUSSION

☐ Purpose, expected benefit and alternatives explained	☐ Correct HER2 medicine and formulation confirmed
☐ Duration and treatment setting discussed	☐ Heart and other required monitoring explained
☐ Supportive medicines and urgent contact advice discussed	☐ Pregnancy / contraception / breastfeeding discussed where relevant
☐ Common, serious and lasting agent-specific risks discussed below	☐ Companion cancer medicines reviewed using their own information

2. REGIMEN / AGENT-SPECIFIC MATERIAL RISKS

Pertuzumab
HER2-TARGETED ANTIBODY

- ☐ Diarrhoea and dehydration
- ☐ Infusion / allergic reaction
- ☐ Heart pumping-function reduction
- ☐ Rash and fatigue

Trastuzumab
HER2-TARGETED ANTIBODY

- ☐ Heart pumping-function reduction / heart failure
- ☐ Infusion or allergic reaction
- ☐ Diarrhoea and fatigue
- ☐ Rare serious lung effects

Discuss the treatment aim, alternatives, expected benefit, serious and lasting risks, fertility/pregnancy precautions, the planned monitoring and who to contact. Review the full longitudinal pathway and confirm which conditional treatments apply.

Individual aim / benefit, alternatives, material risks and questions:

3. CONSENT CONFIRMATION

☐ Expected benefit, important risks and reasonable alternatives discussed

☐ Patient questions invited and answered; patient-specific material risks / priorities considered

☐ Emergency contact / toxicity advice and written information offered where appropriate

☐ Patient understands consent is voluntary and may be withdrawn

Patient / person giving consentDate

Clinician obtaining consentDate